Core Viewpoint - The Portnoy Law Firm is investigating potential claims against the board of directors of AdaptHealth Corp for possible breaches of fiduciary duties and mismanagement [1]. Group 1: Company Overview - AdaptHealth Corp is a supplier of home medical equipment for chronic health conditions such as diabetes, sleep apnea, and wound care [1]. - The company sells medical devices directly to patients and bills their insurance providers, including the Centers for Medicare and Medicaid Services (CMS) [1]. Group 2: Legal Investigation - The investigation focuses on whether the board of directors of AdaptHealth has acted in the best interests of shareholders and managed the company appropriately [1]. - Investors who purchased shares prior to 2021 are encouraged to contact the law firm for discussions regarding their rights and interests [1]. Group 3: Investor Support - The Portnoy Law Firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [2]. - Investors still holding shares of AdaptHealth are urged to reach out for assistance in pursuing claims [2].

Group 1: Investment Opportunities - Three equities are highlighted for their potential to yield large profits during market volatility, particularly in the electronic manufacturing services and healthcare distribution industries [1] - The first company shows strong financial performance with significant sales, margins, and profitability increases, making it a desirable investment for stability and growth [1][3] - The second company demonstrates resilience through effective cash flow management and deleveraging initiatives, presenting a compelling opportunity for investors in the healthcare distribution sector [1][6] Group 2: Company Performance - Celestica (CLS) reported a first-quarter 2024 revenue of $2.21 billion, a 20% increase from $1.84 billion in the same period of 2023, driven by a 38% year-over-year increase in the Communications, Consumer, and Enterprise segment [3][4] - The Advanced Technology Solutions division achieved a segment margin of 4.7% in Q1 2024, up from 4.4% in Q1 2023, despite a 3% decline in sales year-over-year [4] - AdaptHealth (AHCO) generated $49 million in operating cash flow in Q1 2024, down from $140.2 million in Q1 2023, but still reflects resilience in cash flow management [6][7] Group 3: Growth Potential - AdaptHealth has reduced its consolidated debt levels and leverage ratios, with a decrease from 3.16 times at the end of 2023 to 3.12 times at the end of Q1 2024, indicating improved financial standing [7] - Teladoc (TDOC) saw a 9% year-over-year increase in chronic care enrollment, reaching 1.12 million members, which supports long-term profitability and recurring revenue [8] - Teladoc employs AI and data to enhance client interaction and operational efficiency, contributing to its growth strategy and increasing membership base [8][9]

cherrybeans/iStock via Getty Images In the past couple of years, there has been a major bust going on of stocks of companies that came public through SPACs in the 2018-2021 time period. The vast majority of the SPAC deals have struggled, and it has tainted the whole segment. But there are always those who not only survive, but thrive. AdaptHealth (NASDAQ:AHCO) is such a case. It is a rollup that initially struggled with digesting all of its acquisitions. The mergers have stopped, and the company has mad ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 AdaptHealth Corp. (Exact name of registrant as specified in its charter) Delaware 82-3677704 (State of Other Jurisdiction of incorporation or Organization) (I.R.S. Employer Identification No.) 220 West Germantown Pike Suite 250, Plymouth Meeting, Pennsylvania 19462 (Address of principal execut ...

Adapthealth Corporation (NASDAQ:AHCO) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Richard Barasch - Chairman & Interim CEO Jason Clemens - CFO Conference Call Participants Jack Slevin - Jefferies Pito Chickering - Deutsche Bank Eric Coldwell - Robert W. Baird & Co. Richard Close - Canaccord Genuity Kevin Caliendo - UBS Joanna Gajuk - Bank of America Merrill Lynch Operator Good day, everyone, and welcome to today's AdaptHealth First Quarter 2024 Earnings Release. [Operator In ...

AdaptHealth Corp. (AHCO) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -66.67%. A quarter ago, it was expected that this company would post earnings of $0.20 per share when it actually produced earnings of $0.64, delivering a surprise of 220%.Over the last four quarters, the company ...

Exhibit 99.1 FOR IMMEDIATE RELEASE ADAPTHEALTH CORP. ANNOUNCES FIRST QUARTER 2024 RESULTS PLYMOUTH MEETING, Pa. – May 7, 2024 - AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the first quarter ended March 31, 2024. First Quarter Results and Highlights All comparisons are to the quarter ended March 31, ...

The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.For both the biotech and pharmaceutical industries, what happens in the laboratory is critical to success (or failure, on the flip side).Some good news from a clinical trial conducted by Eli Lilly (LLY 0.54%) boosted the share price of the pharmaceutical giant (by 0.5%) on Wednesday, leaving several rivals in the dust. These included device makers ResMed (RMD -5.97%), whose stock suffered a 6% blow, ...

Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Boston Scientific (BSX) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores ...

Investors looking for stocks in the Medical - Products sector might want to consider either AdaptHealth Corp. (AHCO) or Boston Scientific (BSX) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, ...